Adragos Hub

● Live Webinar  ·  25 June 2026 De-Risking Sterile Fill-Finish from Clinical to Commercial How expanded CDMO capabilities, lyophilisation expertise and a flexible facility network help accelerate sterile product success. Sterile product development and manufacturing can be complex. Scale-up, lyophilisation, […]

A Step-by-Step Guide for CMC and Technical Operations Leaders Commercial technology transfer of sterile injectables to a European Contract Development and Manufacturing Organisation involves seven defined stages: CDMO selection and technical due diligence; a formal technology transfer plan and risk […]

Contents Phase 1: Define Your Programme Requirements Phase 2: Due Diligence and Capability Screening Phase 3: Site Qualification and GMP Auditing Phase 4: Assemble the Technical Data Package Phase 5: Stakeholder Governance and Programme Management Phase 6: Technology Transfer from […]

Onboarding a sterile injectable fill-finish Contract Development and Manufacturing Organisation (CDMO) involves eight structured steps: defining your manufacturing requirements, establishing selection criteria, conducting a formal technical audit, completing a feasibility assessment, compiling Chemistry, Manufacturing and Controls (CMC) documentation for European […]

To audit a sterile fill-finish Contract Development and Manufacturing Organisation (CDMO) effectively in 2026, assess nine core areas: quality management systems, contamination control strategy, facility and equipment qualification, technology transfer capability, data integrity controls, analytical and stability services, supply chain […]

How Overall Equipment Effectiveness Predicts Pre-Filled Syringe Capacity at a CDMO Overall Equipment Effectiveness (OEE) is the most reliable indicator of a Contract Development and Manufacturing Organisation’s (CDMO) true available capacity for pre-filled syringe fill-finish. It combines three measurable factors, […]